Condition
LAMA2-MD \(Merosin Deficient Congenital Muscular Dystrophy, MDC1A\)
Total Trials
4
Recruiting
3
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Recruiting3
Withdrawn1
Clinical Trials (4)
Showing 4 of 4 trials
NCT06503367RecruitingPrimary
Observation Study in Patients Age 0-5 Years With LAMA2-related Congenital Muscular Dystrophy
NCT07125040Recruiting
Characterization of the Natural History of LAMA2-RD and Identification of Novel Disease Biomarkers
NCT06924125RecruitingPrimary
Spanish Natural History Study for LAMA2 Muscular Dystrophy
NCT01952028WithdrawnPrimary
LAMA2-related Muscular Dystrophy Brain Study
Showing all 4 trials